Inflammatory licensing endows mesenchymal stem/stromal cells (MSCs) with immunosuppressive activity, but how type 2 cytokines modify this programme remains unclear. Here we show that IL-4 and IL-13 counteract IFN-γ/TNF-α-induced MSC immunosuppression. IL-4/IL-13 co-conditioning diminished MSC-mediated protection against concanavalin A-induced acute liver injury and weakened MSC-associated suppression of T-cell proliferation and macrophage inflammatory activation. These functional changes were accompanied by reduced expression of inducible nitric oxide synthase (iNOS) and immunoregulatory chemokines, together with decreased nitrite accumulation. Genetic deletion of Stat6 substantially attenuated these effects, identifying STAT6 as a major mediator of type 2 cytokine-dependent regulation of MSC function. IL-4/IL-13 also reduced inflammatory cytokine-induced STAT1 nuclear accumulation in a STAT6-associated manner, suggesting a potential downstream regulatory mechanism. In vivo, conditional Stat6 deletion in PDGFRα-expressing stromal cells exacerbated bleomycin-induced lung injury and early fibrotic remodelling, highlighting the context-dependent functions of stromal STAT6. Together, these findings identify IL-4/IL-13–STAT6 signalling as a counter-regulatory pathway that limits MSC immunosuppressive licensing and shapes stromal responses to inflammatory microenvironments.
Li, Yanan, Cao, Lijuan, Wang, Tingting et al. Type 2 cytokines reprogram MSCs through STAT6 to weaken their immunosuppressive potency. // Biology Direct. – 2026. – DOI: 10.1186/s13062-026-01069-8. – URL: https://doi.org/10.1186/s13062-026-01069-8
Li, Yanan, Cao, Lijuan, Wang, Tingting, Wang, Yan, Liu, Yue, Bu, Wenqing, Shao, Changshun, Li, Peishan, Melino, Gerry, Shi, Yufang, Fang, & Jiankai (2026). Type 2 cytokines reprogram MSCs through STAT6 to weaken their immunosuppressive potency. Biology Direct. https://doi.org/10.1186/s13062-026-01069-8
Li, et al. “Type 2 cytokines reprogram MSCs through STAT6 to weaken their immunosuppressive potency.” Biology Direct, 2026. doi:10.1186/s13062-026-01069-8.
@article{Li2026,
title = {Type 2 cytokines reprogram MSCs through STAT6 to weaken their immunosuppressive potency},
author = {Li and Yanan and Cao and Lijuan and Wang and Tingting and Wang and Yan and Liu and Yue and Bu and Wenqing and Shao and Changshun and Li and Peishan and Melino and Gerry and Shi and Yufang and Fang and Jiankai},
journal = {Biology Direct},
year = {2026},
doi = {10.1186/s13062-026-01069-8},
url = {https://doi.org/10.1186/s13062-026-01069-8}
}
Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents in regenerative medicine, with their therapeutic effects increasingly attributed to intercellular communication and microenvironmental regulation rather than...
Background Scleral remodeling with myofibroblast activation and extracellular matrix (ECM) degradation drives myopia, but mechanisms remain unclear. This study explored USP33’s role and its regulatory network. Methods We analyzed GEO...
Background Lung cancer is one of the leading causes of cancer-related mortality worldwide. Understanding the molecular mechanisms underlying lung cancer progression is critical for identifying novel therapeutic targets. This study...